These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 36134459)

  • 1. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
    King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
    Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.
    Nguyen C; Luthra R; Kuti E; Willey VJ
    Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
    Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
    J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization.
    Desai U; Kharat A; Hess CN; Milentijevic D; Laliberté F; Zuckerman P; Benson J; Lefebvre P; Hiatt WR; Bonaca MP
    J Med Econ; 2021; 24(1):402-409. PubMed ID: 33634723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic burden in patients with diagnosis of peripheral arterial disease in a claims database in Japan.
    Hosaka A; Miyata T; Onishi Y; Liao L; Zhang Q
    Clin Ther; 2014 Aug; 36(8):1223-30, 1230.e1-4. PubMed ID: 25012730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
    Margolis J; Barron JJ; Grochulski WD
    J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization and costs of cardiovascular events in patients with atherosclerotic cardiovascular disease in Germany - results of a claims database study.
    Sidelnikov E; Dornstauder E; Jacob C; Maas C; Pinto L; Leidl R; Ahrens I
    J Med Econ; 2022; 25(1):1199-1206. PubMed ID: 36330899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.
    Norhammar A; Bodegard J; Eriksson JW; Haller H; Linssen GCM; Banerjee A; Karasik A; Mamouris P; Tangri N; Taveira-Gomes T; Maggioni AP; Botana M; Thuresson M; Okami S; Yajima T; Kadowaki T; Birkeland KI;
    Diabetes Obes Metab; 2022 Jul; 24(7):1277-1287. PubMed ID: 35322567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States.
    Joish VN; Zhou FL; Preblick R; Lin D; Deshpande M; Verma S; Davies MJ; Paranjape S; Pettus J
    J Manag Care Spec Pharm; 2020 Mar; 26(3):311-318. PubMed ID: 32105172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular event incidence and cost in type 2 diabetes mellitus: a Medicare claims-based actuarial analysis.
    Fitch K; Engel T; Sander S; Kuti E; Blumen H
    Curr Med Res Opin; 2017 Oct; 33(10):1795-1801. PubMed ID: 28641023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population.
    Chung H; Crowe CL; Kong SX; Singh R; Farej R; Elliott J; Williamson T; Willey VJ
    J Manag Care Spec Pharm; 2023 Jan; 29(1):80-89. PubMed ID: 36580126
    [No Abstract]   [Full Text] [Related]  

  • 13. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
    Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis.
    Bangalore S; Shah R; Gao X; Pappadopulos E; Deshpande CG; Shelbaya A; Prieto R; Stephens J; Chambers R; Schepman P; McIntyre RS
    J Med Econ; 2020 Mar; 23(3):262-270. PubMed ID: 31665949
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database.
    Uzoigwe C; Noone J; Liang Y; Ali SN; Gamble C
    Diabetes Ther; 2022 Dec; 13(11-12):1861-1874. PubMed ID: 36239850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular event costs in patients with Type 2 diabetes mellitus.
    Johnston SS; Sheehan JJ; Shah M; Cappell K; Princic N; Smith D; Kalsekar I
    J Med Econ; 2015; 18(12):1032-40. PubMed ID: 26189723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
    Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
    [No Abstract]   [Full Text] [Related]  

  • 18. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
    To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937
    [No Abstract]   [Full Text] [Related]  

  • 19. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
    Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
    J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations.
    Annavarapu S; Ghosh S; Li Y; Moretz C; Shetty S; Prewitt T
    Am J Manag Care; 2020 Jun; 26(6):e166-e171. PubMed ID: 32549065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.